Zevra Therapeutics Inc (ZVRA) Stock Price, Quote & News

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 321 939 3416

Website: zevra.com

Address:

1180 Celebration Boulevard, Suite 103, Celebration, United States

WaynD01 Oct. 4 at 5:22 PM

$ZVRA @sirloud13 I want this in teens before the Q3 earrings and continue go higher from there on earrings

1 · Reply

KemPharm_rocks Oct. 4 at 5:09 PM

$ZVRA enough said 😉

0 · Reply

sirloud13 Oct. 4 at 12:25 PM

$ZVRA break above 10.25,send it to at least 13.25. Inverted head and shoulders setting up on the daily.

2 · Reply

KemPharm_rocks Oct. 4 at 12:05 PM

$ZVRA In two weeks, Neil will have in hand, the EMA’s LoQ. With the FDA approval, ongoing EAP, plus all of the ongoing new data, including the new mechanism of action finding, smooth sailing imo.

1 · Reply

EthanStawk Oct. 4 at 10:56 AM

$ZVRA I disagree with this being a bearish sentiment. Someone thinks the price will be over $13.50 in February, and someone else could've bought the shares today, made $131000, and make another $2.25 per share on 75000 shares if it's over $12. Where exactly is the bearish sentiment?

0 · Reply

WaynD01 Oct. 4 at 1:56 AM

$120M EXIM loan for $CRML and $800M for $NB . This itself will tell how big $NB is going to be. Remember the tweets FROM EXIM bank few weeks ago touting this loan tagging a tiny company called NioCorp!! So whose need is this loan and production? $ZVRA

0 · Reply

SweepCastApp Oct. 4 at 12:59 AM

$ZVRA: Unusual Options Activity Alerted CALL flow observed 750x contracts at Strike price of $12 Exp on 02/20/2026 with Premium of $131K and showing BEARISH Sentiment

0 · Reply

Dworkaholic Oct. 3 at 8:41 PM

$ZVRA why does Robinhood say 9.75?

4 · Reply

WaynD01 Oct. 3 at 6:34 PM

$ZVRA Who is capable of pulling an OPEN on ZVRA ?

0 · Reply

RaySan Oct. 3 at 5:16 PM

$ZVRA Volume shriveled up but not the price. Can w hit $10?

0 · Reply

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Sep 4, 2025, 7:30 AM EDT - 4 weeks ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 28, 2025, 7:30 AM EDT - 5 weeks ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 26, 2025, 7:30 AM EDT - 5 weeks ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 8:43 PM EDT - 7 weeks ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 7 weeks ago

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Jul 28, 2025, 6:00 AM EDT - 2 months ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jul 18, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Jul 16, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

May 29, 2025, 4:35 PM EDT - 4 months ago

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 21, 2025, 7:30 AM EDT - 4 months ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 13, 2025, 10:45 PM EDT - 5 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 5 months ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Apr 17, 2025, 7:30 AM EDT - 6 months ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 7, 2025, 7:30 AM EDT - 6 months ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Mar 31, 2025, 4:12 PM EDT - 6 months ago

Zevra Therapeutics Files Preliminary Proxy

Mar 11, 2025, 8:16 PM EDT - 7 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 7 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Feb 28, 2025, 7:30 AM EST - 7 months ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 27, 2025, 7:30 AM EST - 7 months ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 26, 2025, 9:46 AM EST - 7 months ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 24, 2025, 4:02 PM EST - 7 months ago

Zevra to Participate at Upcoming Investor Conferences

Jan 30, 2025, 7:30 AM EST - 8 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 29, 2025, 4:05 PM EST - 8 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 8, 2025, 11:13 AM EST - 9 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Dec 17, 2024, 7:30 AM EST - 10 months ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 6, 2024, 5:00 PM EST - 10 months ago

Zevra Therapeutics Announces Organizational Changes

Nov 21, 2024, 4:51 PM EST - 11 months ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 13, 2024, 7:12 AM EST - 11 months ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:36 PM EST - 11 months ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 6, 2024, 7:30 AM EST - 11 months ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Sep 20, 2024, 12:08 PM EDT - 1 year ago

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 13, 2024, 9:45 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Aug 7, 2024, 9:34 AM EDT - 1 year ago

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 2, 2024, 5:50 PM EDT - 1 year ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Jul 30, 2024, 8:38 AM EDT - 1 year ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Expands Executive Leadership Team

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Jun 3, 2024, 11:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

May 8, 2024, 2:53 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

WaynD01 Oct. 4 at 5:22 PM

$ZVRA @sirloud13 I want this in teens before the Q3 earrings and continue go higher from there on earrings

1 · Reply

KemPharm_rocks Oct. 4 at 5:09 PM

$ZVRA enough said 😉

0 · Reply

sirloud13 Oct. 4 at 12:25 PM

$ZVRA break above 10.25,send it to at least 13.25. Inverted head and shoulders setting up on the daily.

2 · Reply

KemPharm_rocks Oct. 4 at 12:05 PM

$ZVRA In two weeks, Neil will have in hand, the EMA’s LoQ. With the FDA approval, ongoing EAP, plus all of the ongoing new data, including the new mechanism of action finding, smooth sailing imo.

1 · Reply

EthanStawk Oct. 4 at 10:56 AM

0 · Reply

WaynD01 Oct. 4 at 1:56 AM

0 · Reply

SweepCastApp Oct. 4 at 12:59 AM

$ZVRA: Unusual Options Activity Alerted CALL flow observed 750x contracts at Strike price of $12 Exp on 02/20/2026 with Premium of $131K and showing BEARISH Sentiment

0 · Reply

Dworkaholic Oct. 3 at 8:41 PM

$ZVRA why does Robinhood say 9.75?

4 · Reply

WaynD01 Oct. 3 at 6:34 PM

$ZVRA Who is capable of pulling an OPEN on ZVRA ?

0 · Reply

RaySan Oct. 3 at 5:16 PM

$ZVRA Volume shriveled up but not the price. Can w hit $10?

0 · Reply

WaynD01 Oct. 3 at 5:15 PM

$ZVRA And one more getting to the double digit today - $SLS 8% so far.

0 · Reply

CyberspaceCowboy Oct. 3 at 5:13 PM

$ZVRA giving this one more year, market has gone bananas over 5 year period and we are negative. There are worse performing stocks but if they can’t get it together within a year will they ever get it together?

0 · Reply

WaynD01 Oct. 3 at 4:51 PM

$ZVRA It is a great day for me. Multi day double digit run is continuing in $NB, $DPRO and $RVPH . $ICCM just got the FDA approval . Now the only thing I want to hear is the buy out news of $ZVRA for $25 .

3 · Reply

WaynD01 Oct. 3 at 4:33 PM

$ZVRA Any one in the ICCM ? Their device is just got approved by FDA and I have a small position. Lets see how far the PPS go

0 · Reply

MikeyNJ Oct. 3 at 3:43 PM

$ZVRA November $9 puts bidding $1.45. Nice way to collect premium while we wait. Worst case scenario, you own more shares at $7.55 if the shares get put to you. I just noticed someone sold 100 January $9 puts at $1.72.

2 · Reply

DevAd Oct. 3 at 2:38 PM

$ZVRA

0 · Reply

Torn891 Oct. 3 at 1:52 PM

$ZVRA Can someone please leak the number the failed merger was based on.....we all know this company is swiss cheese with insiders/news. (cough cough pizza party)

1 · Reply

lance1965 Oct. 3 at 1:12 PM

$ZVRA Maybe we can close over $10.00 today !

0 · Reply

EthanStawk Oct. 3 at 12:55 PM

$ZVRA I think big news will be after market on a Friday. I think it's a week or two too early, but it could be any time. I could be wrong but I think it's happening. It's the only thing that makes sense to me, but what else is there to do besides waits, sel cash secured puts and ponficiate on the crazy volume/short volume.

3 · Reply

ZVRA100 Oct. 3 at 5:42 AM

$ZVRA alot of activities in the npc group on facebook today. Especially about getting misdiagnosed and finally learning about npc and miplyffa/miglustat combo.

0 · Reply

WaynD01 Oct. 3 at 2:26 AM

$ZVRA Where is HuntingHighlow? Their group covered the short in the dip and left?

1 · Reply

jemer Oct. 2 at 11:55 PM

$ZVRA

3 · Reply

Market Cap	522.62M
Revenue (ttm)	23.61M
Net Income (ttm)	-105.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-446.89%
Debt to Equity Ratio	0.52

Volume	1,129,100
Avg Vol	1,804,424
Day's Range	N/A - N/A
Shares Out	56.14M
Stochastic %K	80%
Beta	1.49
Analysts	Strong Sell
Price Target	$23.71